Lansoprazole-sulfide, pharmacokinetics of this promising anti-tuberculous agent.

Authors:
Sooraj Baijnath
Sooraj Baijnath
University of KwaZulu-Natal
South Africa
Dr Adeola Shobo, PhD
Dr Adeola Shobo, PhD
McGill University
Dr
Montreal , McGill University | Canada
Hendrik G Kruger
Hendrik G Kruger
University of KwaZulu-Natal
South Africa
Per I Arvidsson
Per I Arvidsson
Uppsala University
Tricia Naicker
Tricia Naicker
School of Health Sciences

Biomed Chromatogr 2017 Dec 13;31(12). Epub 2017 Jul 13.

Catalysis and Peptide Research Unit, University of KwaZulu-Natal, Westville Campus, Durban, South Africa.

Lansoprazole (LPZ) is a commercially available proton-pump inhibitor whose primary metabolite, lansoprazole sulfide (LPZS) was recently reported to have in vitro and in vivo activity against Mycobacterium tuberculosis. It was also reported that a 300 mg kg oral administration of LPZS was necessary to reach therapeutic levels in the lung, with the equivalent human dose being unrealistic. A validated liquid chromatography-tandem mass spectrometric method (LC-MS/MS) for the simultaneous quantification LPZ and LPZS in rat plasma and lung homogenates was developed. We administered 15 mg kg oral doses of LPZ to a healthy rat model to determine the pharmacokinetics of its active metabolite, LPZS, in plasma and lung tissue. We found that the LPZS was present in amounts that were below the limit of quantification. This prompted us to administer the same dose of LPZS to the experimental animals intraperitoneally (i.p.). Using this approach, we found high concentrations of LPZS in plasma and lung, 7841.1 and 9761.2 ng mL , respectively, which were significantly greater than the minimum inhibitory concentration (MIC) for Mycobacterium tuberculosis. While oral and i.p. administration of LPZ resulted in significant concentrations in the lung, it did not undergo sufficient cellular conversion to its anti-TB metabolite. However, when LPZS itself was administered i.p., significant amounts penetrated the tissue. These results have implications for future in vivo studies exploring the potential of LPZS as an anti-TB compound.

Download full-text PDF

Source
http://dx.doi.org/10.1002/bmc.4035DOI Listing
December 2017
12 Reads
1 Citation
1.723 Impact Factor

Publication Analysis

Top Keywords

plasma lung
12
lpzs
9
oral administration
8
lpzs plasma
8
mycobacterium tuberculosis
8
metabolite lpzs
8
lung
5
tissue lpzs
4
lung tissue
4
lpzs amounts
4
limit quantification
4
dose lpzs
4
lpzs experimental
4
experimental animals
4
administer dose
4
prompted administer
4
active metabolite
4
quantification prompted
4
amounts limit
4
determine pharmacokinetics
4

References

(Supplied by CrossRef)
Lansoprazole
Barradell et al.
Drugs 1992
Synthesis and physicochemical studies of copper complex of lansoprazole
Das et al.
Oriental Journal of Chemistry 2009
Straightforward zinc-catalysed reduction of sulfoxides to sulfides
Enthaler et al.
Catalysis Science and Technology 2011
Clinical pharmacokinetics of lansoprazole
Landes et al.
Clinical Pharmacokinetics 1995
Lansoprazole quantification in human plasma by liquid chromatography-electrospray tandem mass spectrometry
Oliveira et al.
Journal of Chromatography B, Analytical Technologies in the Biomedical and Life Sciences 2003

Similar Publications